Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

Rheum in the Court, Law in the Clinic: Health Policy in Global Rheumatology

Glen Rodman  |  December 5, 2023

At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.

Filed under:ACR ConvergenceConditionsGuidanceLegislation & AdvocacyLegislation & AdvocacyMeeting ReportsMeeting ReportsPediatric ConditionsProfessional Topics Tagged with:abortionACR Convergence 2023Juvenile Arthritis (JIA)reproductive rights

Clinical Year in Review: 2023

Samantha C. Shapiro, MD  |  December 4, 2023

SAN DIEGO—At ACR Convergence 2023, Philip Seo, MD, MHS, presented an overview of clinical updates in rheumatology from the past year.

Filed under:ACR ConvergenceBiologics/DMARDsConditionsDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2023ankylosing spondylosisPolymyalgia Rheumatica

Gajus/shutterstock.com

Guidelines for ILD in Systemic Autoimmune Rheumatic Diseases

Ruth Jessen Hickman, MD  |  December 4, 2023

SAN DIEGO—In a scientific session at ACR Convergence 2023, Sindhu Johnson, MD, PhD, and Dinesh Khanna, MD, MSc, discussed ACR’s new guideline on SARDs and ILD.

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsGuidanceMeeting ReportsOther Rheumatic ConditionsSystemic Sclerosis Tagged with:ACR Convergence 2023interstitial lung disease (ILD)

The Great Debate 2023

Ruth Jessen Hickman, MD  |  December 4, 2023

SAN DIEGO—Panelists at ACR Convergence 2023 debate the merits of IL-6 inhibitors vs. glucocorticoids for the initial treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic ConditionsVasculitis Tagged with:ACR Convergence 2023PMR FocusRheumPolymyalgia Rheumatica

Large Vessel Vasculitis

Philip Seo, MD, MHS  |  December 1, 2023

SAN DIEGO—The large vessel vasculitides, including Takayasu’s arteritis and giant cell arteritis, experienced a surge of interest at ACR Convergence 2023. Here, we highlight important points from 10 of the studies presented at this conference.

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:ACR Convergence 2023large-vessel vasculitisPolymyalgia Rheumatica

The Eyes Have It

Jason Liebowitz, MD, FACR  |  November 14, 2023

SAN DIEGO—Many rheumatologists see patients referred for uveitis, and Laura Kopplin, MD, PhD, assistant professor of ophthalmology and visual sciences, University of Wisconsin, Madison, discussed inflammatory disease of the eye at ACR Convergence 2023.

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2023panuveitisUveitis

Glucocorticoids in RA

David S. Pisetsky, MD, PhD  |  November 7, 2023

The historical & continuing roles of glucocorticoids in the treatment of RA are discussed. 

Filed under:Education & TrainingRheumatoid Arthritis Tagged with:GlucocorticoidsRA Resource CenterRheumatoid Arthritis (RA)

FDA Approves New Biosimilar for Adult & Pediatric Arthritis

Michele B. Kaufman, PharmD, BCGP  |  November 6, 2023

This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.

Filed under:Biologics/DMARDsDrug UpdatesPediatric ConditionsRheumatoid Arthritis Tagged with:BiosimilarstocilizumabU.S. Food and Drug Administration (FDA)

RheumMadness 2023: The Results Are In

David L. Leverenz, MD, MEd  |  September 11, 2023

RheumMadness is an online tournament in which a bracket of teams, representing key learning concepts in rheumatology, compete against each other in a series of head-to-head matchups, much like basketball teams in the NCAA’s March Madness. The 2023 tournament theme was The All Star Season. Each team represented one all star article competing to be…

Filed under:Career DevelopmentConditionsEducation & TrainingProfessional TopicsResearch ReviewsResearch RheumRheumatoid ArthritisVasculitis Tagged with:AAV FocusRheumANCA-Associated VasculitisAntibodiescyclophosphamideetanerceptFellowsFellows-in-TrainingGlucocorticoidsonline educationpreclinicalprednisoneRheumatology Research FoundationRheumMadnessrituximabTNF-Alpha inhibitor

Case Report: Giant Cell Arteritis-Related Stroke

Jessica Meek, MD, Anna Coppinger, DO, & Sejal Khan, DO  |  September 10, 2023

Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

Filed under:ConditionsHome SliderVasculitis Tagged with:case reportGCAgiant cell arteritis (GCA)stroke

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences